Jacob Joseph, Nicholas M Pajewski, Rowena J Dolor, Mary Ann Sellers, Letitia H Perdue, Sheronda R Peeples, Adam M Henrie, Nancy Woolard, W Schuyler Jones, Catherine P Benziger, Ariela R Orkaby, Amanda S Mixon, Jeffrey J VanWormer, Michael D Shapiro, Christine E Kistler, Tamar S Polonsky, Ranee Chatterjee, Alanna M Chamberlain, Daniel E Forman, Kirk U Knowlton, Thomas M Gill, L Kristin Newby, Bradley G Hammill, Mine S Cicek, Neely A Williams, Jake E Decker, Jiafu Ou, Jack Rubinstein, Gaurav Choudhary, Raúl J Gazmuri, Kenneth E Schmader, Christianne L Roumie, Camille P Vaughan, Mark B Effron, Rhonda M Cooper-DeHoff, Mark A Supiano, Raj C Shah, Jeffrey C Whittle, Adrian F Hernandez, Walter T Ambrosius, Jeff D Williamson, Karen P Alexander
Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double-blind, placebo-controlled randomized pragmatic clinical trial, will compare high-intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community-dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin...
April 20, 2023: Journal of the American Geriatrics Society